Signs of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
Butobarbital is a sedative and a hypnotic drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Hydrocodone | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Magnesium sulfate | The therapeutic efficacy of Butobarbital can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Butobarbital may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Mirtazapine | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Orphenadrine | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Pramipexole | Butobarbital may increase the sedative activities of Pramipexole. |
| Ropinirole | Butobarbital may increase the sedative activities of Ropinirole. |
| Rotigotine | Butobarbital may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Butobarbital. |
| Suvorexant | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Thalidomide | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Butobarbital. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Butobarbital. |
| Sodium oxybate | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum toxin type A. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Butobarbital is combined with Botulinum toxin type B. |
| Ethanol | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butobarbital. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Butobarbital is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Butobarbital is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Butobarbital is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Butobarbital is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Butobarbital is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Butobarbital is combined with Alaproclate. |
| Naltrexone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Butobarbital is combined with Bezitramide. |
| Morphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Hydromorphone. |
| Meperidine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Butobarbital is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Butobarbital is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Butobarbital is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Butobarbital is combined with Remifentanil. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Butobarbital is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Butobarbital is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Butobarbital is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Dihydromorphine. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Butobarbital is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Butobarbital is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Butobarbital is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Butobarbital is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Butobarbital is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Butobarbital is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Butobarbital is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Butobarbital is combined with Naloxegol. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Butobarbital. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Butobarbital. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Butobarbital. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Butobarbital. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Butobarbital. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Butobarbital. |